Posted by Michael Wonder on 27 Apr 2018
ICER posts draft scoping document on medication-assisted treatments for opioid use disorder
26 April 2018 - Document open to public comment until 16 May 2018; report expected to review buprenorphine implant, extended-release injections.
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of several newer options for medication-assisted treatment (MAT) of opioid use disorder. The scoping document will be open to public comment until 5 pm ET on 16 May 2018.
ICER's upcoming review is expected to assess the effectiveness and value of a recently-approved monthly buprenorphine injection (Sublocade, Indivior), a buprenorphine implant (Probuphine, Braeburn/Titan), and an investigational buprenorphine extended-release injection (CAM2038, Braeburn) currently under review by the FDA. These new therapies will be compared to medications commonly used in MAT such as methadone, buprenorphine/naloxone sublingual film (Suboxone, Indivior), and injectable naltrexone (Vivitrol, Alkermes). This list is tentative and subject to change.
